rheumatology
Medicines

Rheumatic immune adverse effects posing challenges for oncology patients


There are still more questions than answers about rheumatic immune-related adverse events (irAEs) associated with anti-programmed death 1 (PD-1) cancer therapies. However an Australian case series of 36 cancer patients with either rheumatic disease preceding their immunotherapy or who developed de novo rheumatic irAEs after treatment has shed some more light on their presentation, management ...

Already a member?

Enter your email to keep reading.


OR